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Abstract
Misfolded alpha-synuclein (αSyn) is a major constituent of Lewy bodies and Lewy neurites, which are pathological
hallmarks of Parkinson’s disease (PD). The contribution of αSyn to PD is well established, but the detailed
mechanism remains obscure. Using a model in which αSyn aggregation in primary neurons was seeded by
exogenously added, preformed αSyn amyloid fibrils (PFF), we found that a majority of pathogenic αSyn (indicated
by serine 129 phosphorylated αSyn, ps-αSyn) was membrane-bound and associated with mitochondria. In contrast,
only a minuscule amount of physiological αSyn was mitochondrial bound. In vitro, αSyn PFF displayed a stronger
binding to purified mitochondria than did αSyn monomer, revealing a preferential mitochondria binding by
aggregated αSyn. This selective mitochondrial ps-αSyn accumulation was confirmed in other neuronal and animal
αSyn aggregation models that do not require exogenously added PFF and, more importantly, in postmortem brain
tissues of patients suffering from PD and other neurodegenerative diseases with αSyn aggregation (α-
synucleinopathies). We also showed that the mitochondrial ps-αSyn accumulation was accompanied by defects in
cellular respiration in primary neurons, suggesting a link to mitochondrial dysfunction. Together, our results show
that, contrary to physiological αSyn, pathogenic αSyn aggregates preferentially bind to mitochondria, indicating
mitochondrial dysfunction as the common downstream mechanism for α-synucleinopathies. Our findings suggest a
plausible model explaining the formation and the peculiar morphology of Lewy body and reveal that disrupting
the interaction between ps-αSyn and the mitochondria is a therapeutic target for α-synucleinopathies.
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Introduction
Parkinson’s disease (PD) is a common neurodegenerative
disorder in the elderly and its characteristic motor symp-
toms result from the loss of dopaminergic neurons in the
substantia nigra [11, 37]. Mitochondrial dysfunction is
sufficient to cause nigral dopaminergic neuron loss [11],
which is consistent with the idea that these neurons are
selectively vulnerable to various toxic insults [49]. Besides
mitochondria dysfunction, genetic studies have established
a causative role of dominant mutations or multiplication
of SNCA (αSyn gene) in familial PD [8, 23, 38, 45] and the
association of SNCA polymorphism with a higher risk of
idiopathic PD [4], demonstrating a key contribution of
αSyn to PD pathogenesis. αSyn is an intrinsically dis-
ordered protein and is abundantly expressed in neurons
[18, 23]. During the disease, αSyn is subjected to a variety
of post-translational modifications [2]. Among them, the
phosphorylation at serine 129 is most relevant to the
pathogenic process and is commonly used to indicate the
pathogenic αSyn species [1, 14].
In addition to PD, αSyn aggregation is also a common
pathological hallmark for a group of neurodegenerative
diseases known as α-synucleinopathies, which include
PD, dementia with Lewy bodies (DLB), and multiple
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system atrophy (MSA) [15, 17]. A large body of evidence
supports that the aggregation process of αSyn, including
both oligomerization and amyloid fibril growth, is closely
related to the pathogenesis of α-synucleinopathies [23].
Notably, both increased αSyn expression by SNCA multi-
plication [8, 45] and the presence of disease-associate αSyn
mutations can increase the aggregation propensity of αSyn
[10]. Reducing αSyn clearance is also able to increase the
amount of αSyn and thereby enhances αSyn aggregation
and neurotoxicity [33]. Moreover, inoculating preformed
αSyn amyloid fibrils (PFF) into wild-type mice induces
endogenous αSyn aggregation and subsequent nigral
dopaminergic neuron degeneration [29], demonstrating
that αSyn aggregation is sufficient to cause neurodege-
neration. Despite these advances, very little is known about
the detailed mechanism of how αSyn aggregation causes
neurotoxicity and contributes to the pathogenic process.
It has been reported that αSyn may play a role in the
physiology and/or pathology of mitochondrial function
[50]. Even though αSyn does not have a mitochondrial tar-
geting sequence, several groups reported its localization in
mitochondria or mitochondria-associated membranes
(MAMs) [9, 12, 16, 25–27, 44, 47], and showed that αSyn
affects a variety of mitochondrial functions, from Ca2+ sig-
naling, to complex I activity, to mitochondrial morphology
and dynamics [50]. However, given the well-established
presynaptic localization of αSyn and its role in synaptic
vesicle release [5–7, 18, 19, 21], it remains unclear how
much physiological αSyn is mitochondria-associated
and to what extent it affects mitochondrial function.
Moreover, whether the mitochondrial αSyn localization
contributes to the disease process and how it is related
to the other major pathogenic event, αSyn aggregation,
are completely unknown.
Some recent studies started to explore the potential
relationship between pathogenic αSyn species and mito-
chondria. Using a proximity ligation assay (PLA), Di
Maio et al. showed that αSyn oligomer and S129E phos-
phomimic mutant each bind TOM20 on the mitochon-
drial outer membrane and impair mitochondrial protein
import [13]. Using exogenously added αSyn oligomer,
Ludtman et al. showed mitochondrial localization of
αSyn oligomer by PLA and the impairment of mitochon-
drial function [28]. They also showed that increased
endogenous αSyn aggregates in neurons derived from an
SNCA triplication patient were also in the vicinity of
mitochondrial ATP synthase, indicating a mitochondrial
localization [28]. Using human pluripotent stem cells ex-
pressing mutant SNCA, Ryan et al. reported fragmented
mitochondria and the clustering of αSyn aggregates in
the mitochondria of SNCA mutant neurons, but not in
the isogenic control neurons [42]. The methodologies
used in above studies, including transient transfection,
exogenously added αSyn oligomers, SNCA mutant cells,
and heavy dependence on imaging-based analyses,
make it difficult to conclude how much pathogenic
αSyn is associated with mitochondria; whether mito-
chondrial association is a main pathogenic pathway
for αSyn aggregates; whether the mitochondrial
ps-αSyn accumulation occurs in neurons that express
wild-type αSyn at endogenous level, and more
importantly, whether such accumulation occurs in
α-synucleinopathy patients.
To understand the cellular mechanism of αSyn aggre-
gation and the resulting neurotoxicity, we adopted a
highly reproducible primary neuron model developed by
Volpicelli-Daley et al., in which the neuronal accumula-
tion of ps-αSyn was induced by exogenously added PFF
[52]. We took an unbiased approach to study the sub-
cellular localization of ps-αSyn and found that the
majority of ps-αSyn was associated with mitochondria.
This finding was verified in other neuronal and mouse
models and was also confirmed with postmortem brain
tissues from α-synucleinopathy patients. Consistent with
these findings, our in vitro results showed a preferential
binding of mitochondria by aggregated αSyn. Moreover,
we have also showed that the mitochondrial accumu-
lation of ps-αSyn is associated with mitochondrial
respiration defects, suggesting mitochondrial dysfunction
as a downstream consequence of aggregated αSyn.
Materials and methods
Purification of recombinant αSyn and preparation of αSyn
PFF
Mouse αSyn was purified as previously described
[3, 51]. Purified αSyn was dialyzed against PBS buffer
(VWR#97062–732), aliquoted, and stored at − 80 °C.
When needed, aliquots of αSyn were thawed, concen-
trated to 350 μM, and shaken at 37 °C for 7 d at 1000 rpm
to prepare mature mouse αSyn preformed fibrils (PFF)
[51]. PFF was aliquoted and stored at − 80 °C. All PFF
preparations were verified by the thioflavin T fluorescence
assay and by imaging using a Tecnai G2 Spirit TWIN
transmission electron microscope. The purification of
human αSyn and the preparation of hPFF were performed
with the same procedures described above.
Primary neuronal culture
P1 mouse or rat cortical neurons were isolated and cul-
tured essentially according to a previously published
protocol [51]. At 7 d in vitro (DIV), neurons were
treated with or without 140 nM αSyn monomer or PFF.
Treated neurons were cultured as usual and collected
after 8–9 d or after a specified time. PFF was sonicated
before each usage with a water-bath cup-horn sonicator
(Misonix XL2020) at 50% power for 5 min. For pro-
teasomal inhibition, primary neurons were treated with
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DMSO or 100 nM epoxomicin for 8 h, and after incuba-
tion, cell lysates or homogenates were prepared.
Immunofluorescence staining and proximity ligation
assay (PLA)
Neurons at 16 DIV were fixed with 4% formaldehyde in
culture medium at 37 °C for 15min and then per-
meabilized with 0.2% Triton-100 for 10min at room
temperature. PLA staining was performed with anti-
TOM20 (Abcam, 1:100) and anti-αSyn phospho (Ser129)
(Abcam, 1:5000) using Duolink In Situ Detection Reagents
(Sigma# DUO92008), following the protocol provided by
the manufacturer. For immunofluorescence staining, anti-
MAP2 (Sigma, 1:250), anti-αSyn phospho (Ser129)(-
Abcam, 1:1000), and anti-TOM20 (Abcam 1:100) were
used as primary antibodies. Alexa 488-conjugated goat
anti-mouse IgG and Alexa 594-conjugated goat anti-
rabbit IgG (ThermoFisher) were used as secondary
antibodies. Images were visualized with an Olympus
IX83 microscope and a Nikon A1plus-RSi scanning
confocal microscope. The Pearson’s correlation coeffi-
cient was calculated with Nikon Elements Analysis
AR5.11.00 (Nikon). For the proteinase K digestion
experiment in Fig. 1h, fixed neurons were incubated
Fig. 1 PFF treatment induces ps-αSyn in primary neurons. a, b Primary cortical neurons derived from wild-type (WT) and αSyn knockout (KO)
mice were untreated (−) or treated with αSyn monomer (M) or PFF (F) as indicated. c, d Primary cortical neurons derived from OVX mice were
untreated (−) or treated with human αSyn monomer (M) or PFF (F). e, f Primary neurons derived from wild-type mice were untreated (−) or
treated with αSyn monomer (M), αSyn PFF (F), or lysozyme PFF (F/L). ps-αSyn (in a, c, and e) and total αSyn (in a and c) were detected by
immunoblot analysis and GAPDH was used as a loading control. In b, d, and f, ps-αSyn was visualized by immunofluorescence staining (red), and
MAP2 stain (green) was used as a neuronal marker. g Primary neurons, untreated (−) or treated with αSyn monomer (M) or PFF (F), were
sequentially extracted with TBS, 1% Triton/TBS, and 2% SDS/TBS. The presence of ps-αSyn and total αSyn was detected by immunoblot analysis. h
PFF-treated neurons were incubated with or without a 10-min 10 μg/mL PK digestion at 37 °C prior to immunofluorescence staining to detect ps-
αSyn (red) and MAP2 (green)
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with 10 μg/mL proteinase K at 37 °C for 10 min before
the immunofluorescence staining.
Sequential extraction
At DIV 16, neurons were homogenized into TBS buffer
(50mM Tris, 150mM NaCl, pH 7.5), sonicated at 50%
power for 5min (Misonix XL2020), and centrifuged at
100,000×g for 30min at 4 °C. The pellets were resus-
pended in 1% Triton-100 in TBS, sonicated, and centri-
fuged as described above. The supernatant was collected
as the Triton-soluble fraction. The pellet was resuspended
in 2% SDS in TBS.
Differential centrifugation to separate mitochondrial and
cytosolic/microsomal fractions
Primary cortical neurons were washed once with ice-
cold neuronal membrane buffer (NMB, 250 mM sucrose,
20 mM HEPES, 10 mM KCl, 1.5 mM MgCl2, 1 mM
EGTA, 1 mM EDTA, and 1mM DTT, pH 7.5) and then
were homogenized in NMB plus proteinase and phos-
phatase inhibitors (NMB+). Dissected spinal cords of
transgenic mice, or brain tissue from patients were
directly homogenized in NMB+. The homogenates were
centrifuged at 600 × g (for cells) or 700×g (for tissue) at
4 °C for 5 min to remove nuclei and unbroken cells. The
supernatants were used as the postnuclear supernatant
(PNS). To separate mitochondrial and cytosolic/micro-
somal fractions, the PNS was centrifuged at 10,000×g for
5 min at 4 °C. The supernatants were collected as cyto-
solic/microsomal fractions, and the pellets (the mito-
chondrial fraction) were resuspended in NMB+.
Density gradient
For the iodixanol gradient analysis, either PNS or iso-
lated mitochondria were mixed with iodixanol stock so-
lution to reach the final concentration of 36%. The
mixture (0.8 mL) was loaded to the bottom of the ultra-
centrifuge tube. On top of it, 0.8 mL of 31% and 0.8 mL
of 10% iodixanol were sequentially laid. After centrifu-
gation at 52,000×g for 4 h at 4 °C (ThermoFisher rotor
S55-S), 0.2mL fractions were collected from top to bottom.
Discontinuous sucrose gradient analysis was performed as
previously described [53].
Western blots
Samples were separated on 16% SDS polyacrylamide gel
or pre-made 4–20% gradient SDS polyacrylamide gel
(ThermoFisher) and transferred to PVDF membranes
(GE Healthcare). The membranes were fixed with 4%
paraformaldehyde and 0.1% glutaraldehyde for 30 min at
room temperature and probed with various antibodies.
The primary antibodies were anti-αSyn phospho
(Ser129) (Abcam 51,253, 1:2500), anti-αSyn (BD Biosci-
ences clone 42, 1:2500), anti-ATPIF1 (ThermoFisher,
1:1500), anti-ATP5A (Abcam, 1:1000), anti-GAPDH
(Stressgen, 1:1000), anti-Calnexin (Sressgen, 1:1000), and
anti-Syntaxin 6 (Sigma, 1:1000). The HRP-conjugated
goat anti-mouse or anti-rabbit IgG antibodies (Bio-Rad)
were used as the secondary antibodies. Signals were
developed by ECL 2 substrate (Pierce) and scanned with
ChemiDoc (Bio-Rad). The signal intensity was measured
with the FIJI software.
Mitochondrial stress test
Primary cortical neurons were seeded in Agilent Sea-
horse 96-well plate at 1.0 × 104 per well. At DIV 7,
neurons were treated with either αSyn monomer or PFF.
At DIV 14, the oxygen consumption rate was measured
with Seahorse XFe96 (Agilent) after sequentially adding
1 μM oligomycin, 1.25 μM FCCP (carbonyl cyanide-p-tri-
fluoromethoxyphenylhydrazone), and 0.5 μM rote-
none/antimycin A (XF Cell Mito Stress Test Kit from
Agilent).
Animals
C57BL/6J mice were from Van Andel Institute internal
colony. CD (Sprague Dawley) IGS rats were obtained from
Charles River. Transgenic mice expressing human A53T
αSyn from the mouse prion protein promoter (line G2–3,
kindly provided by Dr. Michael Lee, University of
Minnesota) were described previously [24]. The bilateral
intramuscular PFF injection was performed according to a
previously published protocol [43] with slight modification.
Briefly, the PFF used for the intramuscular injection was
prepared by shaking 350 μM αSyn at 1000 rpm for 2 d at
37 °C. PFF was aliquoted and stored at − 80 °C. Before each
injection, PFF was diluted to 0.1 μg/μL and sonicated with
the water-bath cup-horn sonicator (Misonix XL2020) at
25% power for 2 h, and then 10 μL of PFF (0.1 μg/μl) or
10 μL PBS was injected into biceps femoris on each
hindlimb.
Statistical analysis
Statistical analyses were performed with GraphPad
Prism software version 6.05.
Results
PFF-induced ps-αSyn in primary neurons
We first characterized the PFF-induced synucleinopathy
model in primary neurons. Our results showed that add-
ing PFF (Additional file 1: Figure S1) was sufficient to in-
duce the phosphorylation of endogenous αSyn and no
ps-αSyn was detected in PFF-treated primary neurons
derived from αSyn knockout mice (Fig. 1a). Immuno-
fluorescence staining verified that ps-αSyn was accumu-
lated in the neurons labeled with the neuronal marker
MAP2 (Fig. 1b). Using an antibody detecting total αSyn,
we found that the majority of αSyn in PFF-treated
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wild-type or αSyn knockout neurons was cleaved
(Fig. 1a). Because the only αSyn in the knockout neurons
was from PFF, this result suggested that the majority of
the exogenously added PFF was truncated in neurons. The
induction of ps-αSyn was specific to the addition of αSyn
PFF; adding the same amount of αSyn monomer did not
produce ps-αSyn. Moreover, the exogenously added
monomer was barely detectable by immunoblot analysis
after 9 days (Fig. 1a, monomer in αSyn knockout neurons),
suggesting a more rapid clearance than that of exogen-
ously added PFF. The same result was obtained with rat
primary neurons (Additional file 1: Figure S2).
To determine whether the findings can be reproduced
with human αSyn, we cultured neurons derived from the
BAC transgenic mice (OVX mice) that express human
wild-type αSyn at twice the endogenous level of mouse
αSyn and on a mouse αSyn knockout background [20].
These neurons were either untreated or treated with
human αSyn monomer or PFF prepared with human
αSyn (hPFF). Immunoblot analysis (Fig. 1c) revealed that
ps-αSyn was induced in neurons treated with hPFF, but
not in neurons untreated or treated with human αSyn
monomer. Immunofluorescence staining confirmed that
ps-αSyn was in neurons (Fig. 1d).
To ensure that the observed effects were not because
of toxic effects of the amyloid fibrils, we compared αSyn
PFF with fibrils of another amyloidogenic protein, lyso-
zyme (Fig. 1e and f ). The ps-αSyn was accumulated
only in αSyn PFF-treated neurons, not in those treated
with lysozyme fibrils, suggesting the ps-αSyn was likely
resulted from seeding by αSyn PFF.
We also determined the aggregation status of ps-αSyn by
sequential detergent extraction. ps-αSyn was enriched in
Triton- and SDS-soluble fractions, whereas total αSyn in
untreated cells appeared mainly in the TBS-soluble fraction
(Fig. 1g). Immunofluorescence staining revealed that
Fig. 2 Accumulation of PFF-induced ps-αSyn in mitochondria. a PNS prepared from αSyn monomer-treated or PFF-treated primary neurons were
subjected to iodixanol gradient separation. The presence of each protein was detected by immunoblot analyses. b PNS from untreated (−) or
αSyn monomer (M)- or PFF (F)-treated rat primary neurons were subjected to differential centrifugation to separate the mitochondrial and
cytosolic/microsomal fractions, which were verified by immunoblot analyses with antibodies against mitochondrial ATP synthase (ATP5A) and
cytosolic GAPDH, respectively. The ps-αSyn in these fractions was detected by immunoblot analysis. The bar graph in the middle shows the
average ± standard error of mitochondrial ps-αSyn from five independent experiments. “C” represents control. Statistical significance was
determined by one-way ANOVA followed by Dunnett’s multiple comparisons test (F = 322.8; n = 5; p < 0.0001). The bar graph on the right shows
the ratio of ps-αSyn in the mitochondria over ps-αSyn in the cytosolic/microsomal fraction, which was the average ± standard error of three
independent experiments. Statistical significance was determined by paired t-test (n = 3; p = 0.048). * represents p < 0.05. c The mitochondria
isolated from PFF-treated neurons were subjected to iodixanol gradient separation, and the presence of ps-αSyn and the mitochondrial marker
ATPIF1 was detected by immunoblot analyses
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PFF-induced ps-αSyn resisted proteinase K digestion
(Fig. 1h). These results led us to conclude that the majority
of PFF-induced ps-αSyn in primary neurons was aggregated.
Preferential binding of PFF-induced ps-αSyn to
mitochondria
To determine the subcellular localization of ps-αSyn, post-
nuclear supernatant (PNS) was prepared from neurons
treated with αSyn monomer or PFF and subjected to
iodixanol density-gradient separation (Fig. 2a). The major-
ity of total αSyn in monomer-treated neurons remained at
the bottom, co-migrating with the cytosolic marker
GAPDH (glyceraldehyde 3-phosphate dehydrogenase).
The ps-αSyn in PFF-treated neurons, however, migrated
to the upper, membrane-bound fractions. Among mem-
brane markers, ps-αSyn appeared to be concentrated in
Fig. 3 Co-localization of PFF-induced ps-αSyn with mitochondria marker TOM20. a Primary cortical neurons were prepared from OVX mice,
cultured for 7 days, then treated with hPFF (PFF prepared with human αSyn), cultured for another 9 d, and subjected to immunofluorescence
staining with antibodies against ps-αSyn and TOM20. Inserts are enlarged images of the areas indicated by the dashed boxes. b Mouse primary
neurons were treated with PFF and subjected to immunofluorescence staining with antibodies against ps-αSyn and TOM20. Arrows point to the
area with strong ps-αSyn accumulation, but weak TOM20 staining. The Pearson correlation coefficient in a and b was determined from 12
individual cells. Statistic difference was determined by an unpaired t-test (n = 12; p < 0.0001). c A proximity ligation assay (PLA) with antibodies
against ps-αSyn and TOM20 was performed in primary neurons treated with αSyn monomer or PFF. Representative images include left, negative
control (omitting anti-TOM20 antibody); center, αSyn monomer-treated neurons; right, PFF-treated neurons. The bar graph shows average ±
standard error of three independent experiments with six areas quantified per experiment. Statistical analysis was performed with one-way
ANOVA followed by Dunnett’s multiple comparisons test (F = 66.40; n = 6; p < 0.0001)
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the peak fraction of mitochondrial marker ATPIF1
(Fig. 2a), which is similar to the finding using a discontinu-
ous sucrose density gradient (Additional file 1: Figure S3)
[53]. These results led us to hypothesize that the
PFF-induced ps-αSyn may be mitochondria-bound.
We tested this possibility by separating the cell homo-
genates into mitochondrial and cytosolic/microsomal
fractions by differential centrifugation. We found that
majority of ps-αSyn was indeed in the mitochondrial
fraction (Fig. 2b and Additional file 1: Figure S4). To rule
out the possibility that the appearance of ps-αSyn in mito-
chondria fraction was simply due to its aggregation status,
we subjected isolated mitochondria to a density gradient
that was optimized for mitochondria purification. The
ps-αSyn co-migrated with mitochondrial marker ATPIF1
to the top of the gradient (Fig. 2c), confirming its asso-
ciation with the membranous mitochondria.
Immunofluorescence staining was used to determine
the subcellular localization of PFF-induced ps-αSyn.
Compared with ps-αSyn in PFF-treated mouse primary
neurons (Fig. 3b), the human ps-αSyn in hPFF-treated
OVX neurons appeared to be less clumpy or less tightly
packed (Fig. 3a), which presumably reflects the high pro-
pensity of mouse αSyn to aggregate [41]. Nevertheless,
co-localization of ps-αSyn with the mitochondrial outer
membrane protein TOM20 was detected in both
hPFF-treated OVX neurons (Fig. 3a) and in PFF-treated
mouse neurons (Fig. 3b). In mouse neurons, we con-
sistently observed a reduced TOM20 staining in areas
having strong ps-αSyn staining (Fig. 3b, arrows),
which was also observed in PFF-treated rat neurons
(Additional file 1: Figure S5, arrows). We reasoned that
the observation is likely due to the high aggregation pro-
pensity of mouse αSyn, which forms tightly packed aggre-
gates and interferes with the detection of mitochondrial
markers by immunofluorescence staining. To verify the
co-localization of ps-αSyn and TOM20, we performed a
proximity ligation assay (PLA) with antibodies against
ps-αSyn and TOM20 in PFF-treated rat primary neurons.
We found that positive signals were only detected in pri-
mary neurons treated with PFF (Fig. 3c), which supported
our conclusion that the majority of PFF-induced ps-αSyn
is associated with mitochondria.
Aggregated αSyn, but not physiological αSyn,
preferentially binds to mitochondria
To compare the amount of physiological αSyn monomer
and pathogenic αSyn aggregates associated with mito-
chondria, we isolated mitochondria from neurons
treated with αSyn monomer or PFF and then subjected
them to a density gradient. As expected, mitochondria
migrated to the upper fraction (Fig. 4a, top panel). Using
mitochondria isolated from neurons treated with αSyn
monomer, we found little αSyn associated with the
mitochondria (Fig. 4a, second panel). However, in
PFF-treated neurons, a significant amount of αSyn (both
full-length and truncated) was in the mitochondrial frac-
tion, which co-migrated with ps-αSyn (Fig. 4a, third and
fourth panels). Some of the truncated αSyn might derive
from exogenously added PFF because PFF was efficiently
cleaved in these neurons (Fig. 1a). Nevertheless, this result
Fig. 4 Aggregated αSyn preferentially binds to mitochondria. a Mitochondria isolated from αSyn monomer-treated or PFF-treated neurons were
separated by iodixanol gradient, and the presence of mitochondrial protein ATPIF1, total αSyn, and ps-αSyn was visualized by immunoblot
analyses as indicated. The arrowhead indicates the position of full-length αSyn; the arrow indicates the position of truncated αSyn. b Isolated
mitochondria with or without in vitro incubation with αSyn monomer or PFF for 30 min at room temperature were subjected to iodixanol
gradient separation. PFF alone was also subjected to gradient separation as a control. The presence of the mitochondrial ATPIF1 or total αSyn in
each fraction was visualized by immunoblot analyses as indicated
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suggested to us that both full-length and truncated αSyn
aggregates can be associated with mitochondria and that
ps-αSyn only reflects a portion of full-length αSyn.
The large amount of αSyn accumulated in the mito-
chondrial fraction of PFF-treated neurons suggested to
us that aggregated αSyn may have a preference to bind
to mitochondria. To test this possibility, we purified
mitochondria from untreated primary neurons, incu-
bated isolated mitochondria with αSyn monomer or
PFF in vitro, and then subjected the mixture to the
density-gradient analysis. The purified mitochondria
contained very little endogenous αSyn (Fig. 4b, second
panel), which is consistent with the idea that very little
physiological αSyn binds to mitochondria under nor-
mal conditions. After incubation with αSyn monomer
or PFF, the majority of αSyn monomer remained at the
bottom, but the majority of αSyn PFF co-migrated with
the mitochondrial protein ATPIF1 to the upper frac-
tions (Fig. 4b, third and fourth panels). As a control,
αSyn PFF alone (i.e. without incubation with mito-
chondria) was also subject to the gradient separation,
and it remained at the bottom (Fig. 4b, bottom panel).
Therefore, our results suggested that relative to αSyn
monomer, aggregated αSyn preferentially binds to the
mitochondria.
Preferential binding of ps-αSyn to mitochondria in other
neuronal and transgenic mouse models
The mitochondrial accumulation of ps-αSyn in PFF-treated
neurons could be a result of the preferential mitochondrial
binding by PFFs, which subsequently seed the conversion
of endogenous αSyn on the surface of mitochondria. To
rule out this possibility, we tested other neuronal and trans-
genic mouse models that do not require exogenously added
PFF. First, we treated primary neurons with epoxomycin, a
proteasome inhibitor, which is able to induce the accumu-
lation of ps-αSyn (Fig. 5a) [40]. When the PNS prepared
from epoxomycin-treated neurons were separated into
mitochondrial and cytosolic/microsomal fractions, the
ps-αSyn was enriched in the mitochondrial fraction
(Fig. 5b). Second, we used a transgenic mouse model
overexpressing human αSyn carrying the pathogenic A53T
mutation [24]. This mouse model develops spontaneous
neurodegeneration at old age with major pathological
changes in the spinal cord and brain stem [30], and the
disease can be significantly accelerated by intramuscular
PFF inoculation [43]. Immunoblot analysis revealed a huge
amount of ps-αSyn accumulated in the spinal cord of dis-
eased mice, which was not present in young control mice
that received PBS inoculation (Fig. 5c). Notably, regardless
whether the disease occurred spontaneously or accelerated
Fig. 5 Association of ps-αSyn with mitochondria in primary neuron and transgenic mouse models. a ps-αSyn and CCAAT-enhancer-binding protein
homologous protein (CHOP) accumulations in primary neurons treated with the proteasomal inhibitor epoxomicin (Epo) were determined by
immunoblot analyses. b The homogenates prepared from Epo-treated (+) or untreated (−) neurons were separated into mitochondrial fraction
(mito) and cytosolic/microsomal fraction (cyto+ms) by differential centrifugation. The mitochondrial enrichment of proteasomal-inhibition-
induced ps-αSyn, mitochondrial ATPIF1, and the cytosolic marker GAPDH were detected by immunoblot analyses. c An A53T transgenic
mouse was sacrificed at terminal stage of neurodegeneration (T, 305 d of age); Littermates of A53T transgenic mice intramuscularly injected
with PBS (C) or αSyn PFF (F) were sacrificed when the PFF-injected mouse developed terminal neurodegeneration at 67 d after injection (135
d of age). Spinal cord homogenates prepared from these mice were separated into mitochondrial (mito) and cytosolic/microsomal (cyto+ms)
fractions by differential centrifugation. ps-αSyn, total αSyn, mitochondrial ATP synthase (ATP5A), and cytosolic GAPDH were detected by
immunoblot analyses. d Mitochondria isolated from the spinal cords of transgenic mice that received PBS (control) or αSyn PFF (+PFF)
injections were subjected to iodixanol gradient separation, and the presence of ps-αSyn and ATPIF1 was detected by immunoblot analyses
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by PFF-inoculation, the ps-αSyn was mainly found in the
mitochondrial fraction (Fig. 5c). In contrast, the majority
of total αSyn, including the endogenous mouse αSyn and
the αSyn from the human A53T αSyn transgene, was in
the cytosolic/microsomal fraction (Fig. 5c). To rule out
the possibility that the result was influenced by the aggre-
gation status of ps-αSyn, we subjected the mitochondria
fraction to the density-gradient analysis. The majority of
ps-αSyn co-migrated with the mitochondrial marker
ATPIF1 to upper fractions (Fig. 5d), confirming that
ps-αSyn was indeed associated with mitochondria. There-
fore, we concluded that the mitochondrial ps-αSyn
accumulation is not due to exogenously added PFF, but is
an inherent property of αSyn aggregates.
The majority of ps-αSyn was associated with
mitochondria in postmortem brain tissues from α-
synucleinopathy patients
To determine whether ps-αSyn is associated with mito-
chondria in patients’ brains, we tested postmortem patient
brain tissues from various α-synucleinopathies (Additional
file 1: Table S1). As expected, ps-αSyn was detected in the
postmortem tissues from such patients, but not in tissue
from controls (Fig. 6a). When PNS prepared from the
Fig. 6 Association of ps-αSyn with mitochondria in α-synucleinopathy patients’ brain tissues. a ps-αSyn in brains of controls (C) and of MSA (M),
DLB (D), and PD (P) patients was detected by immunoblot analysis; GAPDH or β-actin was used as a loading control. b PNS prepared from
brains of controls or MSA patients were subjected to iodixanol gradient separation. The ps-αSyn, total αSyn, and ATPIF1 were detected by
immunoblotting. c The curve reflects the percentage of ps-αSyn or αSyn in each fraction, which is the average ± standard error of two
control samples and two MSA patient samples that were separated by the gradient individually. d PNS prepared from brains of controls (C)
and MSA (M) patients were separated into mitochondrial (mito) and cytosolic/microsomal (cyto+ms) fractions, which were verified by
immunoblot detection of mitochondrial ATP5A and cytosolic GAPDH. The ps-αSyn and total αSyn in each fraction were detected by
immunoblot analysis. f The cingulate cortex of brains from controls (C), DLB patients (D), and PD (P) patients were subjected to the analyses
described in panel d. Bar graphs in e and g reflect the quantification of data in panels d and f, respectively, which are average ± standard
error of the amount of ps-αSyn and total αSyn in each fraction
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striatum of MSA patient brains was subjected to the dens-
ity-gradient separation, the majority of total αSyn remained
at the bottom, similar to that of controls (Fig. 6b). The
mitochondrial marker ATPIF1 migrated to the upper frac-
tions, but a portion of it remained in the bottom, which
could be due to the disintegration of some mitochondria in
postmortem tissue. Remarkably, the majority of ps-αSyn
migrated to upper fractions of the gradient and
co-migrated with ATPIF1, which is completely different
from total αSyn (Fig. 6b and c). When the homogenates
from MSA patients were subjected to fractionation by dif-
ferential centrifugation, the preferential enrichment of
ps-αSyn in the mitochondrial fraction was obvious (Fig. 6d
and e). Similar results were also observed with homoge-
nates prepared from the cingulate cortex of PD and
DLB patients (Fig. 6f and g). Together, these results
suggest to us that in patients suffering from
α-synucleinopathies, ps-αSyn was also preferentially
associated with the mitochondria.
Mitochondrial ps-αSyn accumulation is associated with
defects in cellular respiration
To determine whether the ps-αSyn accumulation in the
mitochondria affects mitochondrial function, we subjected
the primary neurons treated with αSyn monomer or
PFF to the mitochondrial stress test. The PFF-treated
neurons consistently had a higher number of trifluoro-
methoxy carbonylcyanide phenylhydrazone (FCCP)-unre-
sponsive wells (Additional file 1: Figure S6), indicating a
weaker tolerance to FCCP treatment. More importantly,
both the basal and maximum respiration capacities were
significantly lower in PFF-treated neurons (Fig. 7), indi-
cating that mitochondrial ps-αSyn accumulation does
affect mitochondrial function.
Discussion
Our results revealed a preferential accumulation of
ps-αSyn in the mitochondria, connecting two major
pathogenic events of α-synucleinopathies, i.e., αSyn mis-
folding and mitochondrial dysfunction. The fact that
ps-αSyn from three different α-synucleinopathies was as-
sociated with mitochondria suggests to us that this is a
general property of αSyn aggregates and is independent
of the variable conformations of misfolded αSyn in dif-
ferent diseases [34]. Moreover, our results also showed
that the majority of physiological αSyn is not associated
with mitochondria, which is consistent with previous
studies [5–7, 18, 19, 21] and suggests that the
Fig. 7 PFF treatment of primary neurons causes respiration defects. Mouse cortical neurons treated with αSyn monomer or PFF were subjected
to the mitochondrial stress test measuring oxygen consumption rate. The differences in the basal and maximal respiration levels are shown in the
bar graphs, which represent the average ± standard error of three independent experiments with 15–20 wells of cells per experiment. Statistical
significance was determined by two-way ANOVA (for basal level, F = 33.66; p < 0.0001; for maximal level, F = 48.13; P < 0.0001)
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mitochondrial ps-αSyn accumulation is most likely not
due to the phosphorylation of mitochondria-associated
physiological αSyn. Instead, it is likely resulted from the
inherent preference of pathogenic αSyn aggregates to bind
to mitochondria, which is consistent with findings from
our in vitro mitochondria binding study (Fig. 4b).
Our study also revealed that the mitochondrial ps-αSyn
accumulation is accompanied by defects in mitochondrial
activity. Together with the selective vulnerability of mito-
chondria in the energy-demanding nigral dopaminergic
neurons [36, 48, 49], our findings may explain the fact that
certain αSyn mutations or SNCA duplication cause disease
similar to idiopathic PD [8] and that polymorphism of
αSyn gene could be a risk factor for idiopathic PD [4]. Be-
cause the preferential binding by αSyn aggregates is not
limited to mitochondria from nigral dopaminergic neu-
rons, the ps-αSyn mitochondrial connection may also con-
tribute to the degeneration of other neuronal types, which
may lead to the cognitive and behavioral disturbances in
DLB or PDD (Parkinson’s disease dementia) patients and
in patients carrying SNCA triplication [32, 35, 45]. This
conclusion is consistent with a recent report of fragmen-
ted mitochondria and clustering of αSyn aggregates in the
mitochondria of neurons differentiated from human iPSCs
carrying αSyn mutations [42] and the report of mitochon-
drial dysfunction in neurons differentiated from iPSCs de-
rived from a patient carrying αSyn triplication [28].
Our findings also support the faithfulness of changes
in PFF-induced models [29, 52] to the pathogenesis of
α-synucleinopathies. The study of postmortem human
tissues reflects the end stage of diseases, but the PFF-in-
duced model allows us to study the dynamic cellular conse-
quences of αSyn aggregation. Notably, some ps-αSyn did
appear in the TBS-soluble fraction, and a large portion of it
appeared in the Triton-soluble fraction (Fig. 1g), which
presumably represents various states of polymerization,
from a soluble oligomeric state to an amyloid fibril
state. Because the majority of ps-αSyn co-migrated with
mitochondria (Fig. 2b and c), it is reasonable to predict
that not only αSyn aggregates in the fibril state, but also
some of the αSyn oligomers, bind to mitochondria as well.
Because of the intrinsic tendency of αSyn aggregates to
coalesce [23], binding of αSyn aggregates to mitochondria
is not the end, but rather the middle, of a dynamic process
(Fig. 8). The mitochondria-bound αSyn aggregates may
further coalesce and/or the protein aggregate-bound mito-
chondria may be subjected to cellular clearance system.
Thus, it is plausible to postulate that mitochondrial
dysfunction could result from the accumulation of αSyn
aggregates on or in mitochondria, which may interact
with mitochondrial proteins and interfere with their
normal functions. Alternatively, mitochondrial dys-
function may result from the tendency to coalesce by
mitochondria-bound αSyn aggregates, which will disturb
Fig. 8 A schematic model of Lewy body formation
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the normal mitochondria movement, dynamics, and mor-
phology. When αSyn aggregation becomes overwhelming, it
could also disrupt mitochondria, resulting in fragments
of mitochondrial membranes (Fig. 8). This process, to-
gether with cell’s ability to concentrate misfolded proteins
[22], may ultimately lead to the formation of Lewy Bodies.
It is important to note that the mitochondria-associated
αSyn aggregates remain competent to seed αSyn mono-
mer to form ordered aggregates. While αSyn aggregates in
the middle of Lewy bodies are either already coalesced
without reactive surface or crowded by membranous
structures without the access to αSyn monomer, the αSyn
aggregates on the surface remain competent to seed and
have the accessibility to αSyn monomer (Fig. 8). Thus, in
neurons where αSyn monomer is available, αSyn amyloid
fibrils can be grown on the surface of Lewy bodies, resul-
ting in a ring of densely packed αSyn fibrils that reacts
strongly with antibody during immunohistochemical
staining [31]. Therefore, our model predicts that at the
end stage, Lewy bodies or Lewy neurites may contain
membranous structures, mitochondria, αSyn aggregates
in complex with mitochondria and vesicles, and αSyn
fibrils [31, 39, 46].
Conclusion
Our study provides solid evidence supporting the pre-
ferential binding of pathogenic αSyn species to mitochon-
dria; suggests mitochondrial dysfunction as the common
downstream pathogenic mechanism for αSyn aggregation;
and points out that disrupting the binding of pathogenic
αSyn species to mitochondria could be beneficial to
patients suffering from α-synucleinopathies.
Additional file
Additional file 1: Table S1. Postmortem tissues. Figure S1. Electron
microscopic images of αSyn PFF before and after sonication. Figure S2.
PFF-induced ps-αSyn in rat neurons. Primary cortical neurons were un-
treated (−) or treated with αSyn monomer (M) or PFF (F) as indicated.
The presence of ps-αSyn was detected by immunofluorescence staining
(red), and MAP2 stain (green) was used as a neuronal marker. Nuclei were
stained with DAPI. The lower left panel shows a representative immuno-
blot of ps-αSyn and total αSyn; immunoblot analysis of GAPDH was per-
formed to verify equal loading. The bar graph represents the average ±
standard error of five independent experiments. Statistical significance
was determined by one-way ANOVA followed by a Dunnett’s multiple
comparison test (F = 51.21, n = 5, p < 0.0001). Figure S3. Postnuclear
supernatant (PNS) prepared from PFF-treated primary neurons was sepa-
rated using a discontinuous sucrose gradient, and fractions were collected
from the top to the bottom. The presence of ps-αSyn, mitochondrial ATPIF1,
calnexin (endoplasmic reticulum), and syntaxin 6 (Golgi) in each fraction
were detected by immunoblot analysis. Figure S4. PFF-induced ps-αSyn
accumulated in the mitochondria of mouse primary neurons. PNS of mouse
primary neurons treated with either αSyn monomer (M) or PFF (F) were
separated into mitochondrial (mito) and cytosolic/microsomal (cyto+ms)
fractions. The presence of ps-αSyn, mitochondrial ATP synthase (ATP5A),
and cytosolic GAPDH was detected by immunoblot analysis. Figure S5.
Immunofluorescence staining was performed on PFF-treated rat primary
neurons with antibodies against ps-αSyn and TOM20 as indicated. Arrows
indicate cellular areas with strong ps-αSyn stain, but weak TOM20 stain. The
top and bottom panels are two separated images. Figure S6. PFF-treated
neurons were less responsive to FCCP treatment. The graph represents the
average ± standard error of four independent experiments. The statistic dif-
ference was determined by paired t-test (p = 0.0029; n = 4). (DOCX 1025 kb)
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